Search

Your search keyword '"Osmulskaya, N"' showing total 7 results
Start Over Author "Osmulskaya, N"
7 results on '"Osmulskaya, N"'

1. Pediatric acute lymphoblastic leukemia: multicenter study of the treatment by the protocol ALL IC-BFM 2002

Author

Valiev, T. T., primary, Shervashidze, M. A., additional, Osipova, I. V., additional, Burlutskaya, T. I., additional, Popova, N. A., additional, Osmulskaya, N. S., additional, Aleskerova, G. A., additional, Sabantsev, S. L., additional, Gordeeva, Z. S., additional, Smirnov, V. Yu., additional, Poberezhnaya, O. A., additional, Yuldasheva, S. N., additional, Babich, I. A., additional, Guseynov, V. T., additional, Jalilova, S. N., additional, Korkina, Yu. S., additional, Batmanova, N. A., additional, Kirgizov, K. I., additional, and Varfolomeeva, S. R., additional

Published
2022
Full Text
View/download PDF

2. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

Author

Kreuz, W., Escuriola Ettingshausen, C., Vdovin, V., Zozulya, N., Plyushch, O., Svirin, P., Andreeva, T., Bubanská, E., Campos, M., Benedik-Dolničar, M., Jiménez-Yuste, V., Kitanovski, L., Klukowska, A., Momot, A., Osmulskaya, N., Prieto, M., Šalek, S. Z., Velasco, F., Pavlova, A., Oldenburg, J., Knaub, S., Jansen, M., Belyanskaya, L., and Walter, O.

Published
2016
Full Text
View/download PDF

3. Treatment of acute lymphoblastic leukemia in children by ALL IC-BFM 2002 protocol: results of multicenter retrospective study

Author

Valiev, T. T., primary, Shervashidze, M. A., additional, Osipova, I. V., additional, Burlutskaya, T. I., additional, Popova, N. A., additional, Osmulskaya, N. S., additional, Aleskerova, G. A., additional, Sabantsev, S. L., additional, Gordeeva, Z. S., additional, Batmanova, N. A., additional, Trenina, M. R., additional, Birlyukova, D. V., additional, Kirgizov, K. I., additional, and Varfolomeeva, S. R., additional

Published
2021
Full Text
View/download PDF

4. Non-spherocytic hemolytic anemia caused by erythrocyte pyruvate kinase defiiency: the analysis of genetic defects in pediatric patients, living in Russian Federation

Author

Cherniak, E. A., primary, Sokolova, N. E., additional, Semiglazova, K. V., additional, Lavrentyeva, I. N., additional, Donush, E. K., additional, Plaksina, O. I., additional, Borisova, M. V., additional, Danilyuk, N. A., additional, Mitrofanova, E. S., additional, Baturskaya, I. P., additional, Revina, N. G., additional, Burlutskaya, T. I., additional, Rakov, M. A., additional, Evstratov, A. V., additional, Tselousova, O. M., additional, Lebedev, V. V., additional, Chaplygina, N. V., additional, Koryakina, I. V., additional, Osmulskaya, N. S., additional, Afanasyeva, E. I., additional, Nikonova, O. E., additional, Sokolova, L. I., additional, Tsedenisheeva, E. Kh., additional, Yunusova, I. M., additional, Zauralov, E. O., additional, Osipova, I. V., additional, Aslanyan, K. S., additional, Sipacheva, E. V., additional, Boldyreva, O. P., additional, Kazaryan, G. R., additional, Basharova, E. V., additional, Mann, S. G., additional, Kurnikova, M. A., additional, Raikina, E. V., additional, and Smetanina, N. S., additional

Published
2021
Full Text
View/download PDF

5. Results of a prospective observation on the use of a coagulation factor concentrate VIII concentrate (Octanate®) for the induction of immunological tolerance in patients with an inhibitory form of hemophilia A

Author

Zozulya, N. I., primary, Vdovin, V. V., additional, Svirin, P. V., additional, Andreeva, T. A., additional, Shiller, E. E., additional, Konyashina, N. I., additional, Lavrichenko, I. A., additional, Zalepukhina, O. E., additional, Klimova, N. I., additional, Konstantinova, V. N., additional, Krasheninnikova, O. A., additional, Petrov, V. Yu., additional, Perina, F. G., additional, Osmulskaya, N. S., additional, Mironova, A. V., additional, and Popova, N. A., additional

Published
2020
Full Text
View/download PDF

6. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study

Author

Kreuz, W, Escuriola Ettingshausen, C, Vdovin, V, Zozulya, N, Plyushch, O, Svirin, P, Andreeva, T, Bubanská, E, Campos, M, Benedik-Dolničar, M, Jiménez-Yuste, V, Kitanovski, L, Klukowska, A, Momot, A, Osmulskaya, N, Prieto, M, Šalek, S Z, Velasco, F, Pavlova, A, Oldenburg, J, Knaub, S, Jansen, M, Belyanskaya, L, Walter, O, ObsITI study group, and ObsITI committee

Subjects
Male, poor prognosis for immune tolerance induction, 030204 cardiovascular system & hematology, Immune tolerance, 0302 clinical medicine, Risk Factors, factor VIII/von Willebrand factor concentrate, Prospective Studies, Young adult, Prospective cohort study, Child, Genetics (clinical), immune tolerance induction, biology, Hematology, General Medicine, Prognosis, Drug Combinations, Child, Preschool, factor VIII inhibitors, Female, Bonn protocol, Safety, Adult, medicine.medical_specialty, Adolescent, Haemophilia A, haemophilia A, Hemorrhage, Hemophilia A, 03 medical and health sciences, Young Adult, Von Willebrand factor, Internal medicine, von Willebrand Factor, medicine, Immune Tolerance, Humans, Risk factor, Factor VIII, business.industry, Infant, Interim analysis, medicine.disease, Antibodies, Neutralizing, Surgery, biology.protein, Observational study, business, 030215 immunology
Abstract

Introduction/background Development of neutralizing inhibitors against factor VIII (FVIII) is a major complication of haemophilia A treatment. Aim The ongoing, international, open-label, uncontrolled, observational immune tolerance induction (ObsITI) study evaluates ITI, the standard of care in patients with inhibitors. Patients/methods Forty-eight prospective patients in this interim analysis received a single plasma-derived, von Willebrand factor-stabilized, FVIII concentrate (pdFVIII/VWF) for ITI. According to recommended Bonn protocol, ‘low responders’ at ITI start (2 years since inhibitor diagnosis, inhibitor titre ≥10 BU at the start of ITI, or prior ITI failure). Nonetheless, 34 patients (70.8%) achieved complete success, 3 (6.3%) partial success, 1 (2.1%) partial response; ITI failed in 10 patients (20.8%), all with poor prognosis factors. All six low responders achieved complete success. ITI outcome was significantly associated with inhibitor titre level at ITI start (P = 0.0068), number of poor prognosis factors for ITI success (P = 0.0187), monthly bleeding rate during ITI (P = 0.0005) and peak inhibitor titre during ITI (P = 0.0007). Twenty-two of 35 high responder patients (62.9%) with ≥1 poor prognosis factor achieved complete success. Conclusion Treatment with a single pdFVIII/VWF concentrate, mainly according to the Bonn protocol, resulted in a high ITI success rate in haemophilia A patients with inhibitors and poor prognosis for ITI success.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results